Carcinoma, Non-Small Cell-Lung, Lung Cancer, Lung Neoplasms, Respiratory Tract Neoplasms
Conditions
Keywords
Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histological Type, Thoracic Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Gefitinib, Antineoplastic Agents, Therapeutic Uses, Pharmacologic Actions, Protein Kinase Inhibitors, Enzyme Inhibitors, Molecular Mechanisms of Pharmacological Action
Brief summary
During Phase 1b portion, there will be a dose-escalation of AV-299 (formerly SCH 900105) in combination with the recommended dose of gefitinib in subjects with NSCLC or advanced solid tumor. The objective is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended Phase 2 dose (RP2D) in combination with gefitinib for the Phase 2 portion. The Phase 2 is an open-label, 2-arm, randomized study designed to compare the combination of AV-299 (formerly SCH900105) and gefitinib versus gefitinib alone in clinically selected Asian subjects with previously untreated lung adenocarcinoma who have a high likelihood of harboring activating EGFR mutations. Subjects who progress after initial disease control in the gefitinib alone arm may crossover to the combination arm.
Interventions
BIOLOGICALAV-299 + gefitinib
AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
DRUGGefitinib
Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
Sponsors
AVEO Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Asian ethnicity. * ECOG performance status of 0-2. * Phase 1b (only): Diagnosis of one of the following unresectable NSCLC with or without prior therapy advanced solid tumor that progressed after standard therapy * Phase 2 only: Histologic or cytologic confirmation of unresectable locally advanced or metastatic stage IIIB/IV lung adenocarcinoma with at least one measurable lesion, per Response Evaluation Criteria in Solid Tumors (RECIST-Version 1.1). * Phase 2 only: Never smoker or light ex-smoker. * Available tumor tissue for determination of EGFR mutational status and immunohistochemistry analysis * Adequate hematologic, hepatic, renal and coagulation function * No active central nervous system metastases * Prior radiotherapy is allowed if 14 days from first dose of study drug and toxicity is resolved; additionally in Phase 2 only, ≥1 target lesion not irradiated or with definitive progression after prior radiation therapy. * Agreement to use effective contraception. * Phase 2 only: Subjects on Gefitinib monotherapy arm must have documented CR, PR, or SD for ≥12 weeks prior to disease progression in order to cross over to combination therapy arm.
Exclusion criteria
* Phase 2 only: Prior chemotherapy or prior treatment with epidermal growth factor receptor (EGFR) inhibitor, including both tyrosine kinase inhibitors and monoclonal antibodies. There is no limit to the number of therapies for subject being considered for Phase 1b. * History of neoplasm other than the entry diagnosis. * Pregnancy or lactation. * Myocardial infarction within 6 months prior to initiation of study treatment. * A serious active infection. * Known human immunodeficiency virus infection. * A serious underlying medical condition that would impair the ability of the subject to receive protocol treatment. * A major surgical procedure, open biopsy, or significant traumatic injury. * Thrombotic or embolic events. * Known or suspected allergy/hypersensitivity to any agent given in the course of this trial. * Any condition that impairs absorption of oral agents or the subject's ability to swallow whole pills. * Diarrhea ≥ Grade 2 or active Inflammatory Bowel Disease. * Severe acute or chronic medical, psychiatric, or behavioral condition or laboratory abnormality. * Diagnosis of interstitial lung disease. * Any medications or treatments prohibited by the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase Ib: Dose Limiting Toxicity and Recommended Phase II Dose | Every 4 weeks for the first 4 months of treatment period, every 8 weeks thereaftert |
| Phase 2: Objective Response Rate | Every 4 weeks for the first 4 months of treatment period, every 8 weeks thereafter |
Secondary
| Measure | Time frame |
|---|---|
| Phase 1b: Cmax, Tmax, AUC, t1/2, clearance, and Vd | Every 4 weeks for the first 4 months of treatment period, every 8 weeks thereafter |
| Phase 2: Progression Free Survival, Overall Survival, Safety | Every 4 weeks for the first 4 months of treatment period, every 8 weeks thereafter |
Countries
Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand
Outcome results
None listed